Single Technology Appraisal (STA)

Sofosbuvir for treating chronic hepatitis C [ID654]

Consultation on decision to amend the deferred funding

Dear consultees and commentators

You are invited to comment on the proposal set out in the attached document for extending the statutory period for deferred funding of sofosbuvir in the treatment of hepatitis C, as recommended in the draft guidance.

Providing comments

We prefer to receive comments in electronic format, either by email to TACommD@nice.org.uk or on compact disc. Please use Microsoft Office software products. Comments sent by post should be addressed to Kate Moore, Technology Appraisal Project Manager, at the above address.

In the light of comments received, the NICE Guidance Executive will come to a final conclusion on whether the statutory period of deferred funding should be extended.

In order for your views to be included in the papers for this meeting, your comments must be submitted before **5pm** on **Thursday 11 December**.

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

Submitting confidential information in your response

In line with the Guide to the processes of technology appraisal (September 2014; sections 3.1.23, 3.1.24 and 3.7.28 and), if a comment contains confidential information, it is the responsibility of the responder to provide two versions, one complete and one with the confidential information removed (to be published on NICE's website), together with a checklist of the confidential information. Detailed instructions on sending NICE confidential information relating to an appraisal are available from the project manager.

Equality Issues

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the decision may need changing in order to achieve these objectives In particular, please tell us if the decision:

- could have a different impact on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology;
- could have any adverse impact on people with a particular disability or disabilities.

Please provide any relevant information or data you have regarding such impacts and how they could be avoided or reduced.

Final Appraisal Determination

Following this consultation on extending the period of deferred funding, the final appraisal determination will be released for consideration of appeal and factual error. The standard period for appeal and factual error consideration will apply. Any decision to extend the period of deferred funding may be appealed, providing the case for doing so falls within the grounds of appeal.

Confidentiality and misuse of information

The document released to you today will **not** be made publically available on NICE's website.

I would like to take this opportunity to remind you of the confidentiality agreement and undertaking you have signed and agreed to.

I must emphasise that the document attached with this letter, and its contents, are **confidential**. It is released to you only for the purpose of informing NICE's consideration of the period for statutory funding requirement technology. Accordingly, the document, and its contents, should only be divulged to those individuals within your organisation who need to see it to enable you to prepare your response. You must ensure that anyone who sees this document is aware of its confidentiality.

The use of any information contained within the attached document to make investment decisions regarding any shares or other securities, or the passing of such information to someone else for such use, may constitute insider dealing, which is a criminal offence under section 52 of the Criminal Justice Act 1993. It may also be an offence to encourage someone else to deal in shares or securities, the price of which would be affected by the disclosure to the public of any information contained in the attached document.

As part of NICE's ongoing commitment to reducing its carbon footprint, we issue consultation documents by email only. Please note that the attached e-version will be the only copy of the document you receive unless a formal request for a copy in an alternative format is received. A request can be made by contacting Kate Moore on Kate.Moore@nice.org.uk.

Yours sincerely

Meindert Boysen
Programme Director, Centre for Health Technology Evaluation

Attached:

- NICE's consideration of amending the period for the statutory funding requirement for sofosbuvir in the treatment of chronic hepatitis C